Big Pharma joins £200M UK Biobank sequencing project; Monopar sets terms for $40M IPO
→ The UK Biobank is kicking off an ambitious £200 million project to undertake whole-genome sequencing of 450,000 participants, probing the role that genetics plays in a range of common and chronic ailments including dementia, mental illness, cancer and heart disease. Amgen, AstraZeneca, GlaxoSmithKline and J&J pooled £100 million total in exchange for 9 months of exclusive access, while The Wellcome Trust charity and the UK government each provided £50 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.